Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially develop a novel, fast-acting therapy for treatment-resistant psychiatric disorders.
“We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of CYB003, recently acquired as part of our acquisition of Adelia Therapeutics,” said Cybin CEO Doug Drysdale. “Our focus on reducing the need for health system resources, such as in-clinic therapist time, is an important part of our goal to create scalable, more accessible treatments for mental health disorders.”
As part of the agreement, Cybin plans on applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology to the delivery of CYB003, Cybin’s novel deuterated tryptamine, as a potential therapy for treatment-resistant psychiatric disorders. One of the world’s best-performing ODTs, the proprietary Zydis technology creates a freeze-dried tablet that disperses its contents almost instantly in the mouth without needing water.
Delivering CYB003 in such a way provides significant potential benefits, including allowing for pre-gastric delivery and preventing first-pass metabolism, which could potentially improve the pharmacokinetic profile of the drug. The partnership will include feasibility studies that include manufacturing and analytical testing of ODT doses containing varying quantities of CYB003 alongside different excipients.
“We look forward to working with Cybin to potentially develop a novel and fast-acting therapy for treatment-resistant psychiatric disorders,” said Catalent president of oral and specialty delivery Jonathan Arnold. “The Zydis platform is an ideal technology to leverage for this type of drug formulation, as pre-gastric absorption is crucial for efficacy.”
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
A new study that is being planned by scientists at the University of Calgary, Canada,…
The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…
Izotropic recently published a piece that explores the way AI is redefining breast imaging and…
There is general agreement that the U.S. health care system has issues, but there isn’t…
The closing of the public offering provides the company with critical financial flexibility as it…
Lantern’s RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies.…